Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -20.99
- Piotroski Score 4.00
- Grade Buy
- Symbol (PROG)
- Company Biora Therapeutics, Inc.
- Price $0.88
- Changes Percentage (-3.47%)
- Change -$0.03
- Day Low $0.84
- Day High $0.92
- Year High $6.20
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/10/2022
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $4.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.44
- Trailing P/E Ratio -0.25682346109175
- Forward P/E Ratio -0.25682346109175
- P/E Growth -0.25682346109175
- Net Income $-124,115,000
Income Statement
Quarterly
Annual
Latest News of PROG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
AP Top 25 Extra Points: A week that started on a low note at UNLV ends with program's 1st ranking
Sign up for AP Top 25 Poll Alerts to receive the latest updates. UNLV's football program made headlines due to a quarterback's NIL deal dispute and their first-ever appearance in the AP poll. The team...
By AP NEWS | 7 hours ago -
Opinion | Eric Adams Gives New Meaning to Frequent-Flier Program
Gail Collins and Bret Stephens discuss the controversies surrounding New York's mayor, Eric Adams, and question if accepting perks like discounted flights should lead to resignations. They reflect on ...
By The New York Times | 8 hours ago -
Microsoft Corporation (MSFT) Increases Dividend by 11% and Expands $60 Billion Buyback Program, Morgan Stanley Highlights Attractive Risk/Reward Profile
AI is revolutionizing industries with its efficiency and innovation. Microsoft is a major player in this field, but other AI stocks are also making waves. Sectors like healthcare, finance, manufacturi...
By Yahoo! Finance | 9 hours ago
